Last Updated: 09/06/2026

Gylden Pharma

Oxford

Founded 2016

Synthetic T cell-priming vaccines and immunotherapies for infectious disease

Gylden Pharma is a clinical-stage biotechnology company developing 100% synthetic T cell-priming vaccines and immunotherapies.

Its nanoparticle platform delivers synthetic peptides that stimulate cellular immune responses against intracellular pathogens, providing strain-agnostic protection without cold-chain requirements.

The pipeline targets betacoronaviruses, dengue, pandemic influenza, chikungunya, and bacterial infections. Delivery technologies include microneedle array patches.

The company operates an MHRA-licensed cGMP manufacturing facility at Milton Park, Oxfordshire.

Biopharma Infectious Disease Immunology Drug Delivery

Vaccines T Cell Therapy Peptide Therapeutics GMP Manufacturing

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Previously Known As

Emergex Vaccines Holding Limited

Member of

Milton Park

Similar Companies